.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Queensland Health
Boehringer Ingelheim
Johnson and Johnson
McKesson
Express Scripts
Deloitte
Cerilliant
Farmers Insurance
Medtronic

Generated: November 17, 2017

DrugPatentWatch Database Preview

Ramipril - Generic Drug Details

« Back to Dashboard

What are the generic sources for ramipril and what is the scope of ramipril patent protection?

Ramipril
is the generic ingredient in two branded drugs marketed by West-ward Pharms Int, King Pharms Llc, Aurobindo Pharma Ltd, Cipla, Actavis Elizabeth, Sandoz, Apotex, King Pfizer, Lupin, Zydus Pharms Usa, Invagen Pharms, Ranbaxy Labs Ltd, Watson Labs, Mylan Pharms Inc, Apotex Inc, Teva Pharms, Dr Reddys Labs Ltd, Accord Hlthcare, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Ramipril has forty-six patent family members in thirty-one countries and three supplementary protection certificates in three countries.

There are nineteen drug master file entries for ramipril. Thirty-four suppliers are listed for this compound.

Pharmacology for ramipril

Medical Subject Heading (MeSH) Categories for ramipril

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd
RAMIPRIL
ramipril
CAPSULE;ORAL091604-001Jun 8, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Ranbaxy Labs Ltd
RAMIPRIL
ramipril
CAPSULE;ORAL078849-002Mar 6, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
RAMIPRIL
ramipril
CAPSULE;ORAL076549-004Oct 24, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Invagen Pharms
RAMIPRIL
ramipril
CAPSULE;ORAL078745-004Jun 18, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Accord Hlthcare
RAMIPRIL
ramipril
CAPSULE;ORAL202392-002Apr 15, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
RAMIPRIL
ramipril
TABLET;ORAL090697-001Sep 24, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Accord Hlthcare
RAMIPRIL
ramipril
CAPSULE;ORAL202392-004Apr 15, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-003Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
Actavis Elizabeth
RAMIPRIL
ramipril
CAPSULE;ORAL077513-004Jun 18, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ramipril

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-002Feb 27, 2007► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-003Feb 27, 2007► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-001Feb 27, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ramipril

Country Document Number Estimated Expiration
Germany60022525► Subscribe
Bulgaria106360► Subscribe
Slovakia2692002► Subscribe
Bulgaria110003► Subscribe
Norway331616► Subscribe
CroatiaP20020170► Subscribe
Canada2488370► Subscribe
Australia2005209687► Subscribe
Yugoslavia8502► Subscribe
New Zealand517468► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RAMIPRIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/047United Kingdom► SubscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
80030Netherlands► SubscribePRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C0001Belgium► SubscribePRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
US Department of Justice
Federal Trade Commission
Novartis
Deloitte
Baxter
Teva
McKinsey
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot